Risk factors
Quoin Pharmaceuticals (QNRX) risk factors
Item 1A of every Quoin Pharmaceuticals, Ltd. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors56 risks9 new3 dropped7 reworded
Accumulated deficit grew to $71.0 million by December 31, 2025, raising going concern doubts.
Filed Mar 26, 2026 - FY2024 10-K risk factors50 risks
Quoin Pharmaceuticals faces heavy clinical and regulatory risks with an accumulated deficit of $55.2 million and no commercial revenue. The company relies entirely on third-party manufacturers, suppliers, and clinical trial contractors for its drug candidates. Operations are governed by Israeli law, adding cross-border corporate and acquisition complexities.
Filed Mar 13, 2025